Aclaris Therapeutics Inc (NASDAQ:ACRS) – Equities research analysts at William Blair cut their Q3 2018 earnings per share (EPS) estimates for Aclaris Therapeutics in a report released on Tuesday, October 16th. William Blair analyst T. Lugo now forecasts that the biotechnology company will earn ($1.24) per share for the quarter, down from their prior forecast of ($1.14). William Blair also issued estimates for Aclaris Therapeutics’ Q4 2018 earnings at ($3.46) EPS, FY2018 earnings at ($6.71) EPS, FY2019 earnings at ($3.88) EPS and FY2020 earnings at ($2.50) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.05) by $0.04. The business had revenue of $3.68 million during the quarter, compared to the consensus estimate of $2.76 million. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%.

ACRS has been the subject of a number of other reports. BidaskClub upgraded Aclaris Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, October 13th. Zacks Investment Research raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Wednesday, August 8th. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the company a “buy” rating in a research report on Monday, July 9th. Finally, JMP Securities reduced their price target on Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $41.60.

NASDAQ:ACRS opened at $12.50 on Thursday. The stock has a market cap of $377.04 million, a P/E ratio of -5.06 and a beta of 1.21. Aclaris Therapeutics has a 52-week low of $11.00 and a 52-week high of $27.05.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC lifted its position in shares of Aclaris Therapeutics by 518.4% in the first quarter. Cubist Systematic Strategies LLC now owns 8,361 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 7,009 shares during the last quarter. FMR LLC lifted its position in shares of Aclaris Therapeutics by 31.1% in the second quarter. FMR LLC now owns 3,355,785 shares of the biotechnology company’s stock valued at $67,015,000 after buying an additional 796,805 shares during the last quarter. MetLife Investment Advisors LLC lifted its position in shares of Aclaris Therapeutics by 32.7% in the second quarter. MetLife Investment Advisors LLC now owns 13,157 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 3,244 shares during the last quarter. Millennium Management LLC lifted its position in shares of Aclaris Therapeutics by 839.4% in the first quarter. Millennium Management LLC now owns 110,827 shares of the biotechnology company’s stock valued at $1,942,000 after buying an additional 99,029 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Aclaris Therapeutics by 48.7% in the second quarter. Russell Investments Group Ltd. now owns 73,540 shares of the biotechnology company’s stock valued at $1,468,000 after buying an additional 24,090 shares during the last quarter. 99.75% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Stephen A. Tullman purchased 7,100 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, October 4th. The stock was purchased at an average cost of $14.00 per share, with a total value of $99,400.00. Following the completion of the transaction, the director now owns 177,457 shares of the company’s stock, valued at approximately $2,484,398. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Stephen A. Tullman purchased 6,250 shares of Aclaris Therapeutics stock in a transaction that occurred on Wednesday, August 15th. The shares were bought at an average cost of $15.97 per share, with a total value of $99,812.50. Following the completion of the transaction, the director now directly owns 163,757 shares of the company’s stock, valued at approximately $2,615,199.29. The disclosure for this purchase can be found here. Insiders have purchased 19,950 shares of company stock valued at $298,213 over the last three months. Insiders own 17.00% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Further Reading: Should I follow buy, hold and sell recommendations?

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.